{
    "studies": [
        {
            "identificationModule": {
                "nctId": "NCT01175837",
                "officialTitle": "Short-Term Fasting Prior to Systemic Chemotherapy: A Pilot Feasibility Study"
            },
            "eligibilityModule": {
                "inclusionCriteria": "* Histologically confirmed malignancy\n* Scheduled to undergo 4 or more cycles of chemotherapy (with or without past chemotherapy treatment); NOTE: Acceptable chemotherapy regimens are those that have all drugs infused on the first day of the chemotherapy cycle over a period =\\< 8 hours; EXCEPTION: Continuous 5-FU-containing regimens (such as FOLFOX6 and FOLFIRI) are allowed as both the 5-FU bolus as well as the oxaliplatin and irinotecan administration is completed on day 1 of chemotherapy\n* Life expectancy of \\>= 168 days (6 months)\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Body mass index (BMI) \\> 21 kg/m\\^2\n* Weight loss \\< 5% of body weight in the last 168 days (6 months)\n* Adequate renal function (serum creatinine \\< 1.5 X UNL \\[upper normal limit\\] or creatinine clearance \\> 50 ml/min)\n* Negative pregnancy test done =\\< 7 days prior to registration, for women of childbearing potential only\n* Provide informed consent\n* Ability to complete patient booklet by themselves or with assistance\n* Ability and willingness to undergo \\>= 24-hour fast prior to chemotherapy\n* Willingness to be treated at Mayo Clinic Rochester and be available for follow-up\n* Patient willing to provide blood samples for correlative research purposes\n* Must have minimum age of 18 Years",
                "exclusionCriteria": "* Any of the following:\n\n  * Pregnant women;\n  * Nursing women;\n  * Men or women of childbearing potential who are unwilling to employ adequate contraception throughout the study period\n* Diabetes mellitus undergoing therapy with insulin or oral agents\n* History of low serum glucose (hypoglycemia) or insulinoma\n* History of syncope with calorie restriction in the past or other medical comorbidity, which would make fasting potentially dangerous\n* On daily medication that may not be safely taken without food; NOTE: Any non-essential medications and herbal/vitamin supplements should be held to minimize stomach upset during fasting; vitamin C use is discouraged\n* Active gastric or duodenal peptic ulcer disease\n* History of significant cardiac disease, particularly uncompensated congestive heart failure New York Heart Association (NYHA) grade 2 or more or left ventricular ejection fraction (LVEF) \\< 40% on any prior assessment; NOTE: Assessment of LVEF prior to therapy is not required in the absence of other clinical indicators of heart disease\n* Recent history (\\< 6 months) of cerebrovascular accident or transient ischemic attacks\n* History of gout or elevated uric acid level\n* Psychiatric conditions that preclude adherence to study protocol\n* Serious intercurrent infections or nonmalignant medical illnesses that are uncontrolled or whose control may potentially be jeopardized by the complications of fasting\n* Patients receiving parenteral nutrition\n* Receiving steroids (except dexamethasone given for nausea prevention before chemotherapy)\n* Patients receiving taxotere-containing chemotherapy regimens requiring pre-treatment steroid administration\n* Receiving concomitant treatment with insulin-like growth factor (IGF)-receptor blockers or monoclonal antibodies targeting the IGF ligands\n* Any of the following (prior to registration):\n\n  * =\\< 7 days from the time of a minor surgery;\n  * =\\< 21 days from the time of major surgery;\n  * =\\< 21 days from the time of radiation therapy\n* Currently enrolled in a concomitant clinical trial"
            }
        },
        {
            "identificationModule": {
                "nctId": "NCT03839914",
                "officialTitle": "Randomized, Controlled, Single-blinded Trial to Evaluate the Efficacy and Safety of Intra-wound Administration of Vancomycin Powder as Add-on Prophylactic Intraoperative Antibiotic in Patients at High Risk for Surgical Site Infections After Receiving Open Posterior Spinal Surgery"
            },
            "eligibilityModule": {
                "inclusionCriteria": "1. Female or male adult with age \u226518 years\n2. Undergoing open posterior spinal surgery with instrumentation indicated for spinal deformity, trauma and tumor\n3. Able to understand the nature, scope and possible consequences of participation in the study\n4. Appropriate voluntary written informed consent have been provided by patients\n* Must have minimum age of 18 Years",
                "exclusionCriteria": "1. Has been treated with antibiotics due to primary spinal infection (i.e. spondylodiscitis) within 1 year prior to surgery\n2. Ongoing treatment with antibiotics for other infections\n3. Undergoing minimally invasive surgery or anterior-only surgical approaches or deformity correction surgery for adolescent idiopathic scoliosis (inherent low-risk for surgical site infections18)\n4. Undergoing decompression-only surgery for cervical spine, spinal deformity, trauma and tumors\n5. Has known history of allergy to vancomycin, penicillin and other glycopeptides (teicoplanin)\n6. Has history of vancomycin resistance\n7. Pregnancy"
            }
        },
        {
            "identificationModule": {
                "nctId": "NCT05303714",
                "officialTitle": "Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Multimodal Therapy for Patients With Oligometastatic Peritoneal Gastric Cancer: a Randomized Multicenter Phase III Trial: PIPAC_VEROne"
            },
            "eligibilityModule": {
                "inclusionCriteria": "* Primary resectable gastric cancer with positive peritoneal cytology and/or low burden peritoneal metastases (PCI \u22646) confirmed by laparoscopy\n* Signature of written informed consent\n* ECOG PS 0-1\n* Must have minimum age of 18 Years\n* Must have maximum age of 75 Years",
                "exclusionCriteria": "* Extraperitoneal metastases\n* PCI \\>6\n* Gastro-esophageal junction tumor of esophageal relevance (Siewert I-II)\n* Previous allergic reactions to cisplatin or doxorubicin\n* Hemorrhagic or occlusive manifestation of the primary tumor with palliative surgery needed\n* ASA IV\n* Positivity for EBV, MSI and HER2 on diagnostic biopsies\n* Pregnancy and breastfeeding\n* Contraindication to any drug contained in the chemotherapy regimen\n* Hepatic impairment (AST/ALT\\> 3 times normal values, ALT\\>3 times normal values, Bilirubin\\>1.5 normal values)\n* Ischemic/hemorrhagic stroke in the last 6 months\n* Acute myocardial infarction in the last 6 months\n* Moderate/severe heart failure (NYHA III-IV)\n* Leukopenia\\< 2,000/\u03bcl\n* Thrombocytopenia \\< 100,000/\u03bcl\n* Active hepatitis B or C\n* HIV infection\n* Creatinine clearance less than 30 ml/min"
            }
        },
        {
            "identificationModule": {
                "nctId": "NCT00011414",
                "officialTitle": "Phase I Trial and Pharmacokinetic Study of Tariquidar (XR9576), a P-Glycoprotein Inhibitor, in Combination With Doxorubicin, Vinorelbine or Docetaxel in Pediatric Patients With Refractory Solid Tumors Including Brain Tumors"
            },
            "eligibilityModule": {
                "inclusionCriteria": "Age: Patients must be greater than or equal to 2 and less than or equal to 18 years of age.\n\nDiagnosis: Histologically confirmed solid tumors which may include but are not limited to rhabdomyosarcoma and other soft tissue sarcomas, Ewing's sarcoma family of tumors, osteosarcoma, neuroblastoma, Wilms' tumor, hepatic tumors, germ cell tumors, and primary brain tumors. In patients with brain stem or optic gliomas the requirement for histological confirmation may be waived.\n\nMeasurable/Evaluable Disease: Patients must have measurable or evaluable tumors.\n\nPrior Therapy: The patient's cancer must have relapsed after or failed to respond to frontline curative therapy and there must not be other potentially curative treatment options available. Curative therapy may include surgery, radiation therapy, chemotherapy, or any combination of these modalities.\n\nFor patients receiving doxorubicin on this study, the patient must have had their last dose of radiation therapy at least four weeks prior to study entry; For patients receiving docetaxel or vinorelbine, the patient must have had their last dose of extensive radiation (craneospinal or more than 50 percent of pelvis) at least 4 weeks prior to study entry or last dose of limited field radiation (local) at least 2 weeks prior to study entry.\n\nPatients must have had their last dose of chemotherapy at least 21 days prior to study entry (28 days for nitrosoureas), and their last dose of any investigational cancer therapy at least 30 days prior to study entry.\n\nPatients must have recovered from the toxic effects of all prior therapy before entry onto this trial.\n\nPatients with brain tumors must be on a stable or tapering dose of corticosteriods for 7 days prior to the baseline scan performed for the purpose of assessing response to therapy on this study.\n\nPatients should be off colony stimulating factors such as G-CSF, GM-CSF, erythropoietin, and IL-11 for at least 72 hours prior to study entry.\n\nLifetime cumulative dose of anthracycline: Restrictions on the prior cumulative dose anthracylines only apply to patients who will receive doxorubicin in combination with tariquidar.\n\nThe lifetime cumulative dose of anthracycline must be less than or equal to 300 mg/m(2) in patients who will receive doxorubicin in combination with tariquidar, if the anthracycline was administered as a bolus injection without a cardioprotectant (e.g., dexrazoxane) OR if the patient had mediastinal radiation.\n\nThe lifetime cumulative dose of anthracycline must be less than or equal to 400 mg/m(2), if the anthracycline was administered by continuous infusion or with a cardioprotectant and the patient has not had mediastinal radiation.\n\nPerformance Status: Patients should have an ECOG performance status of 0,1, or 2. Patients who unable to walk because of paralysis or weakness, but who are up in a wheelchair will be considered ambulatory for the purpose of calculating the performance score.\n\nHematologic Function: Patients must have adequate bone marrow function, defined as a peripheral absolute granulocyte count of greater than or equal to 1,500/microL, hemoglobin greater than or equal to 8 gm/dL, and a platelet count greater than or equal to 100,000/microL.\n\nHepatic Function: Patients must have adequate liver function, defined as bilirubin within normal limits, SGPT (ALT) less than 2x the upper limit of normal.\n\nRenal Function: Patients must have an age-adjusted normal serum creatinine OR a creatinine clearance greater than or equal to 60 mL/min/1.73 m(2).\n\nCardiac Function: Patients who will receive doxorubicin must have normal cardiac ejection fraction by echocardiogram. An echocardiogram does not need to be performed in patients who will receive docetaxel or vinorelbine.\n\nInformed Consent: All patients or their legal guardians (if the patient is less than 18 years old) must sign a document of informed consent indicating their understanding of the investigational nature and the risks of this study before any protocol related studies are performed. (This does not include routine laboratory tests or imaging studies required to establish eligibility).\n\nDurable Power of Attorney (DPA): Patients who have brain tumors and who are greater than or equal to 18 years of age will be offered the opportunity to assign a DPA so that another person can make decisions about their medical care if they become incapacitated or cognitively impaired.\n* Must have minimum age of 2 Years\n* Must have maximum age of 18 Years",
                "exclusionCriteria": "Clinically significant unrelated systemic illness, such as serious infections, hepatic, renal or other organ dysfunction, which in the judgement of the Principle or Associate Investigator would compromise the patient's ability to tolerate and of the agents in this trial or are likely to interfere with the study procedures or results.\n\nPatients with a history of bone marrow transplantation within the previous 4 months or extensive radiotherapy (craniospinal radiation, total body radiation, or radiation to more than half of the pelvis) within the previous 4 months.\n\nPregnant or breast feeding females are excluded because tariquidar in combination with a cytotoxic drug may be harmful to the developing fetus or nursing child."
            }
        },
        {
            "identificationModule": {
                "nctId": "NCT05008614",
                "officialTitle": "Continuous Erector Spinae Plane Block Versus Thoracic Epidural Analgesia After Thoracotomy: A Randomized Controlled Assessor-blinded Non-inferiority Trial"
            },
            "eligibilityModule": {
                "inclusionCriteria": "* Patients scheduled to undergo elective thoracotomy for lung cancer\n* European Cooperative Oncology Group 0 or 1\n* American Society of Anesthesiologists (ASA) physical classification I-III\n* Willingness and ability to sign an informed consent document\n* Must have minimum age of 18 Years",
                "exclusionCriteria": "* patients with chronic postoperative pain after thoracic surgery\n* patients undergoing thoracotomy with chest wall resection\n* allergies to anesthetic or analgesic medications\n* patients with coagulopathy or who continue to take anticoagulants\n* preoperative liver or renal dysfunction\n* patients with chronic pain, chronic opioid, analgesic or antidepressant or anticonvulsant use\n* Do not understand our study\n* Medical or psychological disease that can affect the treatment response"
            }
        },
        {
            "identificationModule": {
                "nctId": "NCT05472714",
                "officialTitle": "Integration of Multimodal Cancer Predisposition Genetic Counseling Practices Within the Pediatric Oncology Setting: Video Intervention for Newly Diagnosed Families Undergoing Genetic Testing"
            },
            "eligibilityModule": {
                "inclusionCriteria": "Parents\n\n1. Parent or Legal Guardian of a patient with a new diagnosis of cancer, tumor, or other diagnosis referred for tumor/normal sequencing (proband) in the Cancer Center at the Children's Hospital of Philadelphia (CHOP)\n2. Able to be approached within 1-4 weeks of tumor/normal sequencing\n3. Appropriate to approach per oncology team\n4. No cognitive impairment limiting ability to complete measures\n5. Ability to read and speak English fluently\n\nAdolescent/Young Adult (AYA) probands\n\n1. Child proband receiving germline testing in the Cancer Center at CHOP\n2. Ages 12+\n3. Able to be approached within 1-4 weeks of tumor/normal sequencing\n4. Appropriate to approach per oncology team\n5. No cognitive impairment limiting ability to complete measures\n6. Ability to read and speak English fluently\n* Must have minimum age of 12 Years",
                "exclusionCriteria": "1) Not meeting any of inclusion criteria."
            }
        },
        {
            "identificationModule": {
                "nctId": "NCT02840500",
                "officialTitle": "Quality of Life Study in Patients With Cancer Breakthrough Pain Treated in Palliative Care Units"
            },
            "eligibilityModule": {
                "inclusionCriteria": "* Patients \\> 18 years\n* Patients with advanced cancer\n* Patients attended in Palliative Care Units\n* Life expectancy\\> 3 months\n* Written informed consent\n* Patients with baseline controlled cancer pain with opioids who are diagnosed of breakthrough cancer pain by Davies algorithm\n* Must have minimum age of 18 Years",
                "exclusionCriteria": "* Serious psychiatric disorder, cognitive impairment or any disease or condition that prevents the collection of data\n* Patients with evidence of opioid addiction or history of drug or alcohol abuse"
            }
        },
        {
            "identificationModule": {
                "nctId": "NCT03035500",
                "officialTitle": "Long-term Follow-up After Prostate Cancer"
            },
            "eligibilityModule": {
                "inclusionCriteria": "* Diagnosis of prostate cancer\n* Treated with a definitive surgical procedure at City of Hope\n* At least one year post surgical treatment for prostate cancer\n* No history of recurrent, progressive, or metastatic disease\n* Currently stable disease or no evidence of disease\n* No prior treatment of prostate cancer with radiation or chemotherapy\n* No history of other urologic cancer (e.g., bladder cancer, renal cell carcinoma) in addition to prostate cancer\n\n  * Note: Patients who develop recurrence while participating in the Prostate Cancer Survivorship Clinic will be referred back to their urologist and may resume participation in the Survivorship Clinic when deemed appropriate by their treating physician\n* Must be MALE",
                "exclusionCriteria": "* Current treatment with testosterone replacement or androgen deprivation therapy\n* Treatment for another noncutaneous cancer within the past 2 years"
            }
        },
        {
            "identificationModule": {
                "nctId": "NCT04058600",
                "officialTitle": "Exposure to Virtual Reality as Psychosocial Intervention in Colorectal Cancer Surgery in Hospital Clinic of Barcelona, Spain"
            },
            "eligibilityModule": {
                "inclusionCriteria": "* Diagnosed of colorectal cancer requiring elective surgery.\n* American Society of Anesthesiologists (ASA) I - III.\n* No surgical history.\n* Surgical procedure programmed in the next 6 months.\n* Must have minimum age of 18 Years\n* Must have maximum age of 99 Years",
                "exclusionCriteria": "* Neurologic deficits.\n* Visual disorder.\n* Neuro-psychiatric disorder.\n* Use of neuro-psychiatric drugs.\n* Non-sphincter-preserving surgery."
            }
        },
        {
            "identificationModule": {
                "nctId": "NCT05448300",
                "officialTitle": "Adenoma Detection Using Real-Time Computer-Aided Colon Polyp Detection System to Compare Water Exchange and Air Insufflation - A Randomized Controlled Trial"
            },
            "eligibilityModule": {
                "inclusionCriteria": "* Consecutive patients, undergoing screen, diagnostic or surveillance colonoscopy performed by the participating endoscopists will be enrolled.\n* Must have minimum age of 50 Years\n* Must have maximum age of 80 Years",
                "exclusionCriteria": "* We excluded patients age \\< 50 or \\> 80 years old, undergone colonoscopy in the past 3 years, partial intake of bowel preparation, renal failure, previous colonic resection, scheduled for polypectomy, American Society of Anesthesiology (ASA) Risk Class 3 or higher, and lack of written informed consent."
            }
        }
    ]
}